CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma
Authors:
- 31 January 2025
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 379, 967-981
Abstract
No abstract availableKeywords
Funding Information
- National Health Research Institutes (NHRI-EX114-11401BI, NHRI-EX112-11015BI)
- National Science and Technology Council (113-2314-B-007-002-MY3, NSTC 108-2221-E-007-104-MY5, 113-2628-E-007-022, 112-2628-E-007-020)
- National Tsing Hua University (113QF023E1, 113QF021E1)
This publication has 56 references indexed in Scilit:
- The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinomaHepatology, 2023
- Self-assembly of CXCR4 antagonist peptide–docetaxel conjugates for breast tumor multi-organ metastasis inhibitionActa Pharmaceutica Sinica B, 2023
- Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeatorActa Pharmaceutica Sinica B, 2022
- Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical TranslationAdvanced Science, 2022
- Emerging immunotherapy for HCC: A guide for hepatologistsHepatology, 2022
- The Current Landscape of Immune Checkpoint Blockade in Hepatocellular CarcinomaJAMA Oncology, 2021
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in miceHepatology, 2014
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen–positive myeloid cell infiltration in miceHepatology, 2013
- Dual‐Function CXCR4 Antagonist Polyplexes To Deliver Gene Therapy and Inhibit Cancer Cell InvasionAngewandte Chemie International Edition, 2012